AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $41.45.

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reduced their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Truist Financial decreased their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. HC Wainwright downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating and cut their target price for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. Finally, Guggenheim reduced their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th.

AnaptysBio Stock Down 1.0 %

NASDAQ:ANAB opened at $14.21 on Monday. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31. The stock has a fifty day simple moving average of $18.67 and a 200-day simple moving average of $28.13. The company has a market capitalization of $432.40 million, a PE ratio of -2.34 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, equities analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

Insider Activity

In other news, Director Ecor1 Capital, Llc acquired 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its position in AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the period. FMR LLC raised its holdings in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares during the period. Jennison Associates LLC acquired a new position in AnaptysBio during the 3rd quarter worth approximately $8,874,000. Victory Capital Management Inc. boosted its holdings in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.